Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health (GH) is a leader in precision oncology, pioneering non-invasive liquid biopsy tests for cancer detection and monitoring. This dedicated news hub provides investors and healthcare professionals with timely updates on the company's financial performance, clinical advancements, and strategic initiatives.
Access authoritative coverage of earnings reports, regulatory milestones, and technology innovations shaping cancer diagnostics. Our curated collection includes press releases on clinical trial results, partnership announcements, and peer-reviewed research developments directly from Guardant Health's communications.
Key updates cover FDA clearances for diagnostic assays, global commercialization efforts, and data partnerships advancing precision medicine. Stay informed about developments in molecular residual disease detection, expanded test indications, and reimbursement progress affecting healthcare adoption.
Bookmark this page for consolidated access to verified information about liquid biopsy advancements and GH's role in transforming cancer care through genomic insights. Check regularly for objective reporting on developments impacting both clinical practice and investment considerations.
Guardant Health reported a 25% increase in Q4 revenue to $78.3 million and a 34% yearly increase to $286.7 million in 2020. Notably, precision oncology revenue grew 31%, supported by a 70% rise in clinical testing. The company launched Guardant Reveal and expanded its partnership with Vall d’Hebron Institute of Oncology. Despite these gains, operating expenses surged 110% to $141.1 million in Q4, leading to a net loss of $93.7 million. Looking ahead, Guardant expects 2021 revenue between $360 million and $370 million.
Guardant Health (Nasdaq: GH) announces its participation in two upcoming virtual investor conferences. The 10th Annual SVB Leerink Global Healthcare Conference will feature a fireside chat on February 26 at 1:20 p.m. PT. Additionally, the Cowen 41st Annual Health Care Conference will hold a fireside chat on March 2 at 8:10 a.m. PT. Interested parties can access live and archived webcasts on the company’s website. Guardant Health is a leader in precision oncology, focusing on blood tests and advanced analytics to improve cancer patient outcomes and lower healthcare costs.
Guardant Health, Inc. (Nasdaq: GH) will report its fourth quarter and full year 2020 financial results after the market closes on February 24, 2021. A conference call to discuss these results will follow at 2:00 p.m. Pacific Time/5:00 p.m. Eastern Time, available for live streaming on the company’s website. Guardant Health is at the forefront of precision oncology, providing proprietary blood tests and advanced analytics to improve cancer care and outcomes. Their tests include Guardant360® and GuardantOMNI®, aiming to enhance early-stage cancer detection and management.
Guardant Health (Nasdaq: GH) reported findings from a study in JCO Precision Oncology demonstrating that its Guardant360 liquid biopsy detects 23.6% more actionable mutations compared to tissue biopsies for advanced non-small cell lung cancer (NSCLC). In a cohort of 186 patients, the liquid biopsy showed similar treatment responses and progression-free survival. The study advocates for a 'blood-first' approach, addressing challenges like insufficient tissue samples which affect 30% of patients. CEO Helmy Eltoukhy emphasized the need for broader adoption of liquid biopsies following recent FDA approval for the Guardant360 CDx test.
Guardant Health, Inc. (Nasdaq: GH) and Vall d’Hebron Institute of Oncology (VHIO) have formed a partnership to establish liquid biopsy testing services at VHIO's facility in Barcelona, Spain. This service aims to enhance access to genomic testing for cancer patients, starting with private patients and expanding to the public healthcare system. The partnership will support clinical trial eligibility assessments and accelerate cancer therapeutics research. Guardant Health's tests are backed by extensive clinical evidence and have received both CE mark and U.S. FDA approvals.
Guardant Health (Nasdaq: GH) will showcase significant data on its blood tests at the virtual 2021 ASCO Gastrointestinal Cancers Symposium from January 15-17, 2021. The presentations will focus on the clinical utility of Guardant’s liquid biopsy technology in screening and treating colorectal cancer. CEO Helmy Eltoukhy emphasized the importance of these tests in tracking treatment responses and early detection of cancer recurrence. Notable highlights include the Guardant Reveal™ test and the LUNAR-2 ECLIPSE trial aimed at early detection in average-risk adults.
Guardant Health (Nasdaq: GH) announced its participation in the 39th Annual J.P. Morgan Virtual Healthcare Conference, scheduled for January 11 at 7:50 a.m. PT / 10:50 a.m. ET. The event will feature a presentation by the company's management, accessible via a live and archived webcast on their website. Guardant Health specializes in precision oncology, offering blood tests and analytics that enhance cancer care. Their platforms, including Guardant360® and GuardantOMNI®, focus on advanced cancer treatment and early detection strategies.
Guardant Health, Inc. (Nasdaq: GH) has appointed Michael Bell as its new Chief Financial Officer (CFO), effective January 5, 2021. He succeeds Derek Bertocci, who retired after four years with the company. Bell brings over 25 years of finance experience from companies such as CareDx and Novartis Diagnostics. CEO Helmy Eltoukhy emphasized Bell's capability to enhance the company's financial operations and support its goal of transforming cancer care. Guardant Health specializes in precision oncology through proprietary blood tests and advanced analytics.
Guardant Health, Inc. (Nasdaq: GH) presented new findings at the 2020 Virtual San Antonio Breast Cancer Symposium, showcasing its GuardantINFORM™ platform. This tool provides critical insights into treatment responses in patients with ER-positive, HER-2 negative metastatic breast cancer, emphasizing the issue of treatment resistance. Key abstracts revealed molecular tumor evolution and resistance mechanisms. With over 135,000 patient data points in its database, GuardantINFORM aims to enhance targeted drug development and clinical trials in oncology.
Guardant Health has priced an offering of $1 billion in 0% convertible senior notes due 2027, set to settle on November 19, 2020. The notes will not accrue interest and have an initial conversion rate of 7.1523 shares per $1,000, representing a conversion price of around $139.82, a 34% premium over its recent stock price. The company expects net proceeds of approximately $984.3 million, intended for corporate purposes, including research and development and potential acquisitions. Additionally, capped call transactions are in place to reduce dilution from the notes' conversion.
FAQ
What is the current stock price of Guardant Health (GH)?
What is the market cap of Guardant Health (GH)?
